Growth hormone deficiency and cerebral palsy

Jesús Devesa1,2, Nerea Casteleiro2, Cristina Rodicio2, Natalia López2, Pedro Reimunde1,21Department of Physiology, School of Medicine of Santiago de Compostela, Spain; 2Medical Center Proyecto Foltra, 15886 Teo, SpainAbstract: Cerebral palsy (CP) is a catastrophic acqui...

Full description

Bibliographic Details
Main Authors: Jesús Devesa, Nerea Casteleiro, Cristina Rodicio, et al
Format: Article
Language:English
Published: Dove Medical Press 2010-09-01
Series:Therapeutics and Clinical Risk Management
Online Access:http://www.dovepress.com/growth-hormone-deficiency-and-cerebral-palsy-a5238
id doaj-df563b9982f04807a7eb35b7d86f7c64
record_format Article
spelling doaj-df563b9982f04807a7eb35b7d86f7c642020-11-25T00:25:08ZengDove Medical PressTherapeutics and Clinical Risk Management1176-63361178-203X2010-09-012010default413418Growth hormone deficiency and cerebral palsyJesús DevesaNerea CasteleiroCristina Rodicioet alJesús Devesa1,2, Nerea Casteleiro2, Cristina Rodicio2, Natalia López2, Pedro Reimunde1,21Department of Physiology, School of Medicine of Santiago de Compostela, Spain; 2Medical Center Proyecto Foltra, 15886 Teo, SpainAbstract: Cerebral palsy (CP) is a catastrophic acquired disease, occurring during development of the fetal or infant brain. It mainly affects the motor control centres of the developing brain, but can also affect cognitive functions, and is usually accompanied by a cohort of symptoms including lack of communication, epilepsy, and alterations in behavior. Most children with cerebral palsy exhibit a short stature, progressively declining from birth to puberty. We tested here whether this lack of normal growth might be due to an impaired or deficient growth hormone (GH) secretion. Our study sample comprised 46 CP children, of which 28 were male and 18 were female, aged between 3 and 11. Data obtained show that 70% of these children lack normal GH secretion. We conclude that GH replacement therapy should be implemented early for CP children, not only to allow them to achieve a normal height, but also because of the known neurotrophic effects of the hormone, perhaps allowing for the correction of some of the common disabilities experienced by CP children.Keywords: growth hormone, IGF-I, cerebral palsy, short stature http://www.dovepress.com/growth-hormone-deficiency-and-cerebral-palsy-a5238
collection DOAJ
language English
format Article
sources DOAJ
author Jesús Devesa
Nerea Casteleiro
Cristina Rodicio
et al
spellingShingle Jesús Devesa
Nerea Casteleiro
Cristina Rodicio
et al
Growth hormone deficiency and cerebral palsy
Therapeutics and Clinical Risk Management
author_facet Jesús Devesa
Nerea Casteleiro
Cristina Rodicio
et al
author_sort Jesús Devesa
title Growth hormone deficiency and cerebral palsy
title_short Growth hormone deficiency and cerebral palsy
title_full Growth hormone deficiency and cerebral palsy
title_fullStr Growth hormone deficiency and cerebral palsy
title_full_unstemmed Growth hormone deficiency and cerebral palsy
title_sort growth hormone deficiency and cerebral palsy
publisher Dove Medical Press
series Therapeutics and Clinical Risk Management
issn 1176-6336
1178-203X
publishDate 2010-09-01
description Jesús Devesa1,2, Nerea Casteleiro2, Cristina Rodicio2, Natalia López2, Pedro Reimunde1,21Department of Physiology, School of Medicine of Santiago de Compostela, Spain; 2Medical Center Proyecto Foltra, 15886 Teo, SpainAbstract: Cerebral palsy (CP) is a catastrophic acquired disease, occurring during development of the fetal or infant brain. It mainly affects the motor control centres of the developing brain, but can also affect cognitive functions, and is usually accompanied by a cohort of symptoms including lack of communication, epilepsy, and alterations in behavior. Most children with cerebral palsy exhibit a short stature, progressively declining from birth to puberty. We tested here whether this lack of normal growth might be due to an impaired or deficient growth hormone (GH) secretion. Our study sample comprised 46 CP children, of which 28 were male and 18 were female, aged between 3 and 11. Data obtained show that 70% of these children lack normal GH secretion. We conclude that GH replacement therapy should be implemented early for CP children, not only to allow them to achieve a normal height, but also because of the known neurotrophic effects of the hormone, perhaps allowing for the correction of some of the common disabilities experienced by CP children.Keywords: growth hormone, IGF-I, cerebral palsy, short stature
url http://www.dovepress.com/growth-hormone-deficiency-and-cerebral-palsy-a5238
work_keys_str_mv AT jesampuacutesdevesa growthhormonedeficiencyandcerebralpalsy
AT nereacasteleiro growthhormonedeficiencyandcerebralpalsy
AT cristinarodicio growthhormonedeficiencyandcerebralpalsy
AT etal growthhormonedeficiencyandcerebralpalsy
_version_ 1716174177748123648